Abstract: A charge control system of one or more batteries B is electrically connected with one or more solar panels S, so configured to obtain the maximum transfer of power from such one or more solar photovoltaic panels S and for controlling the charge of the one or more batteries B. The control system includes: at least one tracking device of the point of maximum power or MPPT 2 adapted to adjust one of its input impedance seen from panels S for a power adaptation with panel S; at least one protection circuit of the system 3 adapted to avoid damages to the charge control system caused by inverted currents, coming from such battery B and from one or more electric equipment 8 connected with it.

Abstract: A charge control system of one or more batteries B is electrically connected with one or more solar panels S, so configured to obtain the maximum transfer of power from such one or more solar photovoltaic panels S and for controlling the charge of the one or more batteries B. The control system includes: at least one tracking device of the point of maximum power or MPPT 2 adapted to adjust one of its input impedance seen from panels S for a power adaptation with panel S; at least one protection circuit of the system 3 adapted to avoid damages to the charge control system caused by inverted currents, coming from such battery B and from one or more electric equipment 8 connected with it.

Abstract: Pharmaceutical compositions containing unit or separate dosages of 2.5 to 5 grams of reduced glutathione (GSH) and known anti-tumor agents, to be used simultaneously, separately or sequentially in anti-tumor therapy.Compounds of the invention, that can be used both in mono- or polychemotherapy, reach surprising results against tumors, thus avoiding the onset of dangerous side-effects, such as nephrotoxicity induced by cisplatinum, and increasing the long term survival rates.